Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Canagliflozin Hemihydrate: Unveiling SGLT2 Inhibitor Dyna...
2025-09-29
Explore the advanced role of Canagliflozin hemihydrate, a potent SGLT2 inhibitor, in dissecting glucose homeostasis and renal glucose reabsorption for cutting-edge metabolic disorder research. This in-depth analysis uniquely investigates dynamic assay design, mechanistic selectivity, and translational boundaries, setting it apart from existing guides.
-
Canagliflozin Hemihydrate: SGLT2 Inhibition and Pathway S...
2025-09-28
Explore how Canagliflozin hemihydrate, a potent SGLT2 inhibitor, enables advanced glucose metabolism research by offering unparalleled pathway selectivity. This article uniquely analyzes its specificity, contrasts with mTOR inhibition, and provides best practices for metabolic disorder studies.
-
Canagliflozin Hemihydrate: Advanced Insights for SGLT2 In...
2025-09-27
Explore the advanced scientific role of Canagliflozin hemihydrate as a small molecule SGLT2 inhibitor for glucose metabolism research. This article offers a deeper, pathway-centric analysis of its selectivity, experimental design, and research frontiers in metabolic disorder studies.
-
Canagliflozin Hemihydrate: Novel Research Horizons in SGL...
2025-09-26
Explore the unique applications of Canagliflozin hemihydrate as a small molecule SGLT2 inhibitor for advanced glucose metabolism research. This article uncovers experimental strategies and differentiates Canagliflozin’s mechanistic profile from mTOR-targeted approaches, offering new perspectives for diabetes mellitus research.
-
AZD0156 and ATM Inhibition: Metabolic Reprogramming as a ...
2025-09-25
Explore how the potent ATM kinase inhibitor AZD0156 reveals novel metabolic vulnerabilities in cancer therapy research by modulating macropinocytosis and DNA damage response pathways. This article offers a distinct, integrative perspective on metabolic adaptation and checkpoint control modulation, advancing the understanding of selective ATM inhibition.
-
c-Myc tag Peptide: Systems Biology Insights for Cancer an...
2025-09-24
Explore how the c-Myc Peptide revolutionizes research into transcription factor regulation and cancer biology. Uniquely, this article connects synthetic c-Myc peptide applications with systems-level insights, including immune signaling and autophagic regulation.
-
Triptolide and Transcriptional Regulation: New Insights f...
2025-09-23
Explore the multifaceted role of Triptolide in modulating transcriptional networks, genome activation, and matrix metalloproteinase inhibition. This article examines Triptolide as a potent IL-2/MMP-3/MMP7/MMP19 inhibitor, highlighting its applications in cancer and developmental biology research.
-
br Introduction Adenosine deaminase ADA also known as
2025-03-03
Introduction Adenosine deaminase (ADA), also known as adenosine aminohydrolase, is a key enzyme involved in the purine metabolism that converts adenosine to inosine irreversibly (Lupidi et al., 1997). It is a zinc containing metalloenzyme present in both prokaryotes and eukaryotes. In humans ADA
-
Recently several groups including ours
2025-03-03
Recently, several groups, including ours, have started to use the C. elegans multi-dendritic PVD neurons as a model system to dissect the molecular mechanisms of dendrite development. During larval development, PVD elaborates complex and stereotyped dendritic arbors by sequentially adding primary (1
-
The following are the supplementary data related to this
2025-03-03
The following are the supplementary data related to this article. Conflict of interest Acknowledgements Disclosure of interest Introduction Since the introduction of platinum-based chemotherapy, metastatic testicular cancer has become a curable disease and most testicular cancer patient
-
The GRAVY value for a
2025-03-03
The GRAVY value for a protein is calculated as the sum of hydropathy values of all the amino acids, divided by the number of residues in the sequence (Kyte and Doolittle, 1982). According to Kyte and Doolittle (1982) integral membrane proteins typically have higher GRAVY scores than do globular pro
-
We also show that in both
2025-03-01
We also show that in both ATM proficient and deficient/mutant UNC 0631 the activation of ATR signaling is DSB complexity-dependent (Figs. 1, 4A, C and E, 6A and B). Wang et al. have also reported that the effects of ATR and CHK1 on radiosensitivity are independent of the NHEJ repair pathway [41], [
-
ASK has been identified as an
2025-03-01
ASK2 has been identified as an ASK1 binding protein (Wang et al., 1998). ASK1 supports the stability and active configuration of ASK2 in the heteromeric complex, while ASK2 has been found to activate ASK1 by direct phosphorylation (Takeda et al., 2007). Unlike ASK1, which is ubiquitously expressed i
-
br Aromatase inhibitors The aromatase
2025-03-01
Aromatase inhibitors The aromatase enzyme, P450arom, belongs to the super-family of P450 proteins which includes more than 480 members divided in 74 different families. P450arom is a unique member of family 19 [39], and is located in the endoplasmic reticulum of mammalian Z-YVAD-FMK that express
-
Introduction Preeclampsia a serious hypertensive disorder th
2025-03-01
Introduction Preeclampsia, a serious hypertensive disorder that can occur during pregnancy, is a pregnancy-related disease characterized by the onset of BMS 753 and proteinuria after the 20 t h week of gestation, and it occurs in about 5% of all pregnancies [1]. If left untreated, preeclampsia can